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Highlights 
 
- The design of new biocatalysts requires a detailed knowledge of the reaction to 
be catalysed. 
- The combination of experimental and computational techniques is a very 
reasonable strategy.  
- New enzymes have been designed by combination of de novo techniques with 
laboratory evolution. 
- Kemp, Diels-Alder and retro-aldol reactions have been used to illustrate recent 
achievements.  
- Flexible molecular models treated by QM/MM multiscale methods can be used 
in future studies. 
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Abstract 
In this contribution, recent developments in the design of biocatalysts are reviewed with 
particular emphasis in the de novo strategy. Studies based on three different reactions, 
Kemp elimination, Diels-Alder and retro-aldolase, are used to illustrate different success 
achieved during the last years. Finally, a section is devoted to the particular case of 
designed metalloenzymes. As a general conclusion, the interplay between new and more 
sophisticated engineering protocols and computational methods, based on molecular 
dynamics simulations with Quantum Mechanics/Molecular Mechanics potentials and 
fully flexible models, seems to constitute the bed rock for present and future successful 
design strategies. 
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1. Introduction 
Enzymes are biological catalysts that speed up chemical reactions making them 
compatible with life. Often, these catalysts show important advantages with respect to 
non-natural catalysts such as their chemo-, regio- and stereoselectivity and the ability to 
work under mild conditions of temperature and presure. Although the knowledge about 
the origin of enzymatic efficiency to catalyse chemical reactions is still not complete, 
there have been numerous studies that have provided a solid understanding about some 
of the key factors in biocatalysis.1,2,3,4  
Many reactions employed in the chemical and biochemical industry need of efficient 
catalysts to improve their rate, their selectivity and their environmental friendship. 
Obviously enzymes are excellent candidates to fulfil these requirements but, in order to 
extend their applicability to different purposes under different conditions, they must be 
modified using protein engineering techniques. First, enzymes need to be stable enough 
in different conditions of pH, temperature, solvent composition and substrate 
concentration. In addition, many of the chemical reactions carried out in the industry do 
not have a natural counterpart and then new enzymes with new functions should be 
developed. During the last years, different protein designs have been proposed to 
catalyse new chemical reactions. These designs can be classified, according to the 
strategy used in their development, into those based on directed evolution, rational 
design, or a combination of them named as semi-rational design.5  
Directed evolution6 applies to strategies based in natural evolution to tailor the 
properties of molecules instead of organisms.7 Random mutations or recombination can 
be done to evolve proteins in the laboratory identifying the successful variants by 
screening or by selection. New proteins with new desired functions can be obtained 
after some mutations or recombining protein fragments. The advantage of this strategy 
is that no structural information is needed and that distant regions of the sequence space 
can be explored. However, in most cases changes introduced far from the active site 
provoke minor effects in the kinetic properties of the protein. Another limitation of this 
strategy is that a minimum threshold of activity is required to start the cycles of 
mutations and screening. 
Although in the next future we should be able to design a particular amino acid 
sequence that will fold into a particular structure with the desired function, rational 
design refers, in these days, to the introduction of direct mutations of selected residues 
on specific positions of an already existing protein.8 Mutations of few residues can lead 
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to important changes in the active site while the global structure of the protein remains 
essentially unaltered. These mutations are driven by the analysis of the data obtained 
from different sources, ranging from X-ray to simulations. In particular, when 
computational analysis of the enzymatic activity is used to guide the mutations, one 
usually refers to this strategy as computational design.9  
These two strategies can be combined into an efficient procedure for the design of new 
proteins with new functions. In the semi-rational approach a new function is obtained 
from rational design and the activity of the resulting protein is improved by means of 
several directed evolution cycles. 
The strategies for the computational design of new enzymes can start from different 
protein scaffolds. These can be i) immune-globulins, proteins that were already used to 
produce catalytic antibodies (CAs) more than thirty years ago;10 ii) a promiscuous 
protein showing catalytic properties for a secondary reaction that is redesigned to 
improve or to change this activity; and iii) a protein without specific catalytic properties 
that is used as a scaffold to support a design from scratch, or de novo design, of a new 
activity.9,11 The first group of proteins, CAs, are obtained using as hapten a Transition 
State Analogue (TSA), a stable molecule resembling the Transition State (TS) structure 
of the reaction. While showing certain catalytic activity, their efficiency is low 
compared to that of natural enzymes, which can be attributed to either the nature of 
immune-globulins, to the lack of adequacy of the TSA to the real TS of the target 
reaction, or to the fact that these proteins bind the products so tightly that is the major 
flaw in their ability to rival enzymes for catalytic efficiency. The use of these proteins in 
the design process seems to decline in the last years. Instead, other protein structures 
seem more adequate for the process of designing new biocatalysts. The active sites of 
natural enzymes are an obvious starting point for this process. These active sites, 
composed by few residues that promote a particular chemical reaction, can be 
redesigned for a new function after few mutations.12 This redesign process can take 
advantage from the different promiscuous behaviours that can appear in a natural 
enzyme. Enzymes promiscuity with respect to different substrates, different catalytic 
activities or different reaction conditions provides the raw material for the redesign of 
new properties.13 The promiscuous activity in natural enzymes, which could be already 
known or discovered by chance, can be also induced by rational design or directed 
evolution. Finally, de novo design is based in the knowledge of the chemical reaction to 
be catalysed and, in particular, in the TS and the physicochemical principles governing 
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its stabilization (see Figure 1). This information is obtained from computational 
simulations. Mayo and co-workers pioneered the field of the de novo design of 
enzymes14 converting the E. coli protein thioredoxin into a primitive esterase. In 
particular, a histidine nucleophile was introduced into an engineered surface active site 
reaching a 180-fold rate acceleration. The process made use of the ORBIT program to 
identify enzyme-like active sites within a pre-existing protein scaffold.15 This program 
explores simultaneously the conformational and sequence space of the designed 
biocatalysts.16 The actual boom in de novo design starts with three significant works 
about three different reaction for which no natural enzymes are known: the Kemp 
elimination,17 the Diels-Alder reaction18 and the retro-aldolase reaction.19 In all the three 
cases, which will be described in the following sections, the design process employed 
the Rosetta software developed at University of Washington. A previous step for the 
design process is the knowledge of the reaction TS and the design of a minimalist active 
site to stabilize its charge distribution. This active site, often known as a ‘theozyme’,20 
consists of disembodied amino acids placed at adequate positions around the substrate 
to promote the reaction. At this stage, quantum mechanical methods are needed to 
properly localize the TS in this reduced model, as far as changes happen at the 
electronic level. In the next step the minimal active site model must be placed into an 
existing protein structure, what is done using the RosettaMatch module.21 This module 
tests different protein scaffolds grafting the ‘theozyme’ at each of the possible active-
site positions. After trying different rotamers, a match is obtained when the substrate 
can be positioned without clashing to the protein backbone and key interactions 
observed in the ‘theozyme’ are conserved. The third step of the process is the design of 
the resulting candidates to optimize the surrounding residues for catalysis.22,23 This step 
consists in several cycles of sequence design and protein optimization. For this purpose 
protein residues are classified as designable or repackable, according to their distance to 
the ligand. The optimization or packing procedure is based in a simple repulsive 
potential. The last step consists in the ranking or scoring of the designed sequences.24,25 
The hundreds or thousands of resulting designs must be evaluated before production. 
With this purpose each of the resulting designs is scored using different criteria that 
include ligand affinity and protein stability. Only those better placed in the final ranking 
will be expressed and tried experimentally.   
Different improvements have been incorporated to this strategy during the last years. 
Usually, programs for protein design consider fixed the backbone of the protein during 
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the design and optimization steps26 although, for instance, Rosetta program was recently 
modified to consider flexible backbones.27 The optimization in the sequence space can 
be expanded considering also non-canonical amino acids.28,29,30 Algorithm 
improvements have been also achieved taking advantages of player strategies and social 
evolution.31 Obviously, although Rosetta is probably the best-known suite of programs 
for enzyme design, there exist alternatives. For instance, the matching of the ideal 
‘theozyme’ into an existing protein scaffold can be also carried out with OptGraft,32 
Scaffold-Selection,33 and PRODA_MATCH.34,35 A different strategy is employed by 
the SABER program.36 Instead of placing the ideal active site into selected proteins, this 
program searches for proteins already presenting the catalytic residues in the adequate 
relative positions, thus requiring the introduction of a lower number of mutations. 
 
 
Figure 1. Schematic representation of the de novo design of new enzymes 
 
 
In spite of all these improvements the de novo design strategy still suffers from 
limitations, as demonstrated by the fact that the rate of successful designs is quite low 
and, in addition, the best ones display reaction rate enhancements far from those of 
natural enzymes.  As pointed out by Baker,37 a design can fail at different levels: i) the 
proposed ‘theozyme’ can be not a perfect model for the real TS of the enzymatic 
reaction, ii) the active site designed into a given protein scaffold can be distorted with 
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respect to the ideal geometry, and iii) the effect of the long range electrostatic 
interactions and/or protein dynamics can be incompatible with catalysis. In addition, a 
more complete design strategy should not consider exclusively the TS stabilization but 
the whole reaction process and, in particular, the differential stabilization of the TS with 
respect to the reactants. In other words, the enzyme must be designed considering not 
only the preorganization of the active site around the TS but also the reorganization that 
occurs during the chemical process and that can impose an energy penalty during the 
barrier climbing process. In a review published in 2008, we already distinguished 
between “structure-based strategies” and “reaction analysis-based strategies”.7 Enzyme 
designs based in a ‘theozyme’ would fall in the first category while the limitations 
pointed out in current strategies could be overcome with methods that make use of the 
analysis of reaction profiles. Obviously the computational cost of this second strategy, 
which is based in the use of Molecular Dynamics (MD) with hybrid Quantum 
Mechanics/Molecular Mechanics (QM/MM) potentials, is much higher and then it has 
to be used in combination with the first one. 
Many excellent reviews about the design of new biocatalysts have been recently 
published.5,7,9,11,38,39,40,41,42,43,44,45 This review will focus mainly on the advances 
obtained in the field of the de novo design during the last years, emphasizing the new 
achievements of the different computational strategies employed in the design process. 
The three aforementioned reactions, Kemp, Diels-Alder and retro-aldolase, will be used 
to illustrate these points. An additional section will be devoted to the particularities of 
the design of metal-containing enzymes.  
 
2. Kemp elimination 
The Kemp elimination, that consists in the conversion of benzisoxazoles into 
salicylonitriles, is a well-studied reaction that takes place by means of an E2 elimination 
mechanism (see Scheme 1). The reaction implies a proton transfer from a carbon atom 
of the substrate to a base, thus creating an anion species with the concomitant opening 
of the ring.46,47,48 The reaction appear to be very sensitive to the base strength, having 
tested hydroxide ion,46,47 amines46,47 or the conjugated base of acids.48 Since no 
naturally occurring enzyme has been identified to catalyse the reaction, and together 
with the fact that it is not a very complex reaction, it has been used as a benchmark of 
different protocols to design new enzymes. 
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Scheme 1. Representation of the base-catalyzed Kemp elimination 
 
2.1. Antibodies and other catalysts 
The first designed biocatalysts of Kemp elimination (34E4 and 35F10), with rate 
acceleration greater than 108, were catalytic antibodies generated in response to a 
positively charged hapten mimicking the TS geometry.49 Other cationic haptens have 
been used to get catalytic antibodies that catalyze this reaction, such as 4B2 and 6C2,50 
or the 13G551, being the latter, together with the previously mentioned 34E4, the ones 
showing the highest catalytic activity. Following a similar experimental protocol, an 
antibody with an active site consisting of a hydrophobic pocket with a conserved lysine 
residue was generated against a reactive diketone hapten. This antibody, 38C2, showed 
activity for a variety of reactions that proceed via an enamine intermediate and, 
interestingly, also present promiscuous activity for the base-catalysed Kemp 
elimination.52 
The use of X-ray diffraction has allowed obtaining details, at atomic level, of the 
structures of the originally designed catalytic antibodies, as well as variants generated 
by mutation of key residues. Analysis of these structures together with kinetic studies, 
has contributed to the elucidation of the key features responsible of the catalytic activity 
of these new enzymes. Thus, the active site of 34E4 shows conformational plasticity 
that can be responsible of a reduced efficiency since only one of the possible 
orientations of the substrate is reactive. An optimal microenvironment must be present 
in the hydrophobic pocket to impose the proper positioning of the substrate to interact 
with the conjugated base, usually Glu or Asp, and to modulate the pKa of the base, since 
water molecules could stabilize their non-protonated form. It has been also observed 
that buried water molecules found in the active site can stabilize the negatively charged 
developed in the phenoxide oxygen atom of the substrate. Finally, π stacking 
interactions between a Trp residue and the highly polarizable TS has been also proposed 
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as the origin of catalysis in 34E4.53,54,55 In the case of 13G5 antibody, solved X-ray 
structures suggest that Asp and Glu would act as a base to abstract the proton from the 
substrate and to orient a water molecule to stabilize the leaving group, respectively.56 
Kemp elimination is dramatically sensitive to the medium, as illustrated by the fact that 
the reaction with acetate is over 107 folds slower in water than in acetonitrile, as a 
consequence of the stabilization of carboxylate anions in aqueous environments.57 
Theoretical studies based on quantum chemical calculations on model systems in gas 
phase have been used to propose the most appropriate base and acid moieties to predict 
catalytic functionalities and to design haptens to produce improved catalytic 
antibodies.58 
Two independent investigations showed that familiar “off-the-shelf” proteins, serum 
albumins, catalyse the same Kemp elimination at similar rates than the previous 
catalytic antibodies. In this case, the base was a lysine side-chain amino group located 
in a hydrophobic pocket.59,60,61 It has been demonstrated that these albumin based 
catalysts, that uses a lysine as a base, are less sensitive to the environment. Based on 
quantum mechanical optimized geometries on gas phase and in solution represented by 
continuum models, this different environmental dependent behaviour has been 
rationalized.62 
A different scaffold employed to design a catalyst for the Kemp elimination has been 
the polyethyleneimine, highly branched polymers with primary, secondary and tertiary 
amines linked by ethylene units that can be modified by alkylation or acylation of their 
amine groups. These enzyme-like catalysts were named as synzymes.63 More recently, a 
new Kemp bio-catalysts has been designed by a single mutation in a small regulatory 
protein calmodulin (CaM). Native CaM, upon binding Ca(II), opens the hydrophobic 
pockets in each of its domains which, when introducing a dehydrated carboxylate, 
allows its accommodation to productively interact with the Michaelis complex and 
stabilize the TS of the reaction.64,65 Additionally, this new enzyme serves as a calcium 
ion sensor. Engineering of model protein cavities to catalyse the Kemp elimination has 
been also obtained by a single mutation of Met to His in the artificial L99A cavity in T4 
Lysozyme.66 The presence of the new catalytic base, His, that abstract the proton from 
the substrate in a hydrophobic buried cavity is enough to catalyse the process, 
demonstrating that protein model cavities may provide templates for studying protein 
design in simplified environments. 
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These studies demonstrate the possibility of designing new enzymes by a reduced 
number of mutations in the native protein scaffold. Nevertheless, the catalytic efficiency 
of these new biocatalysts is still far from the most efficient enzymes.  
 
2.2. de novo design of new enzymes 
The first example of de novo protein design for Kemp elimination was published in 
2008 by Houk, Tawfik, Baker and co-workers using the strategy described in the 
introduction.17 The significance of this new protocol based on cutting-edge 
computational methods was emphasized by Nanda, who stressed the importance of 
combining experimental and computational tools.67 In their work, different non-
immunoglobulin proteins were used as starting scaffolds selected by means of Rosetta 
software.24,25,26 In particular, from previously designed theozymes computed by means 
of quantum mechanical calculations in reduced models, two active-site motifs were 
considered differing in the choice of catalytic base; one utilized a carboxylate group for 
benzisoxazole deprotonation, whereas the other exploited a histidine side chain backed 
up by an aspartate or glutamate to regulate its pKa and tautomeric state. In addition, a 
hydrogen-bond donor was provided to stabilize the developing negative charge on the 
phenolic oxygen atom, and π –stacking interactions were included for TS stabilization. 
Fifty-nine designs, each containing 10 to 15 mutations, were experimentally 
characterized and eight of them resulted to be active. The X-ray diffraction analysis of 
one of the newly produced enzymes, KE07, was solved and demonstrated to 
superimpose well with the computational model. Interestingly, although the best 
computationally designed enzyme was more than one order of magnitude less efficient 
than comparable antibody catalysts, their activity was significantly improved by 
directed evolution.17 KE07 was used as a template for further incorporation of up to 8 
mutations providing a 106-fold rate acceleration, but with a marked decrease in the 
overall stability.68 In a different study using the KE70 as template, new computationally 
guided optimizations where carried out including backbone flexibility. This, combined 
with further directed evolution render a 400-fold increased activity.69 The highest active 
new catalyst originally obtained by Tawfik and co-workers, KE59, presented the 
inconvenience of being the least stable. The strategy to improve the performance of this 
template was to carry out a number of fold-stabilizing mutations prior to directed 
evolution cycles. Sixteen rounds of mutation and selection led to more than 2,000-fold 
increase in catalytic efficiency.70  
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Jorgensen and co-workers studied free energy surfaces to explore the reaction 
mechanism of four of the designed Kemp elimination catalysts17 by means of free-
energy perturbation (FEP) methods within hybrid QM/MM potentials based on Monte 
Carlo (MC) simulations.71 Some approximations were considered in the simulations, 
like keeping the protein backbone fixed, the use of a semiempirical Hamiltonian (PM3) 
to describe the QM region, or keeping the interatomic distance between the proton 
donor and acceptor atoms as constant. According to their results, the catalytic 
mechanisms of Kemp elimination catalysed by KE07, KE10(V131N), KE15 were found 
to be concerted with proton transfer more advanced in the TS than the breaking of the 
isoxazolyl N-O bond, while a step-wise mechanism preceded by the proton transfer was 
found for the KE16. The trend predicted from the computed free energy barriers, by 
comparison with the experimental rate constants, was not encouraging.71 The 
application of this strategy to the study of the mechanism of KE59, KE70 and several 
mutants rendered similar conclusions.72 The study of the effect of the mutation 
Glu50Asp in the 34E4 catalytic antibody, showed an increase in the free energy barrier 
of 2.4 kcal·mol-1,73 in good agreement with experimental observation. Again, the same 
methodology allowed justifying the promiscuity of the 4B2 antibody in catalysing the 
allylic isomerization and the Kemp elimination reactions.74  
Different approaches based on density functional theory (DFT) methods, ranging from 
reduced models in gas phase to those including the full protein and solvent water 
molecules in ONIOM QM/MM MD simulations, were carried out by Houk and 
coworkers to rationalize the experimental data of several designed catalysts of Kemp 
elimination.75 Computed activation barriers were in qualitative agreement with 
experiments, allowing distinguishing the inactive from the active catalysts but with a 
weak correlation with the energy barriers deduced from the experimentally determined 
rate constants. 
Warshel and coworkers45,76,77 have recently pointed out that the design of a new catalyst 
must be focused not only in placing the reacting fragments in proper places around the 
substrate but in optimizing the full environment preorganization. This preorganization 
accounts for the required electrostatic properties of the enzyme to lower the activation 
free energy of the reaction, a property that depends not only on residues of the active 
site. Using an Empirical Valence Bond (EVB) approach, these authors studied several 
Kemp eliminases (catalytic antibodies, albumines and de novo designs) remarking the 
difficulties of designing a correctly preorganized environment adapted for the small 
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changes in the electronic distribution observed during the formation of the TS. A larger 
preorganization of the environment is closely related to a smaller reorganization of the 
protein needed to attain the TS of the reaction. This reorganization implies an energy 
penalty that should be minimized to improve the catalysts design, an aspect that was 
emphasized also by Labas et al.78  
A different approach, based on studies of failed designs of new enzymes, has been 
applied for the development of more efficient catalysts. In particular, Mayo and co-
workers used an iterative approach starting from an inactive protein scaffold, HG-1, that 
was designed to convert the xylan binding pocket of a thermostable xylanase into a 
Kemp eliminase.79 Based on MD simulations and analysis of structures obtained from 
X-ray crystallography, the authors found that the inactivity could be due to bonded 
waters and high flexibility of residues in the active site. These findings guided the 
design of a more embedded binding pocket, which moved the active site deeper into the 
protein and resulted in an active Kemp eliminase, HG-2. MD simulations of this last 
structure let to an additional mutation that provided a better packing around the 
substrate by reducing the active site conformational heterogeneity observed in HG-2. 
The new designed protein, HG-3, exhibited activity comparable to the best Rosetta 
design.79 This new catalyst was proved to be particularly amenable to direct evolution 
based on multiple rounds of mutagenesis and screening. The turnover number for proton 
transfer of the best variant obtained in the Hilvert laboratory after 17 rounds of 
mutagenesis and screening, HG3.17, was comparable to the efficiency of many natural 
enzymes.80 The three factors that were suggested to be decisive in the improvement of 
the Kemp eliminase activity from HG-3 to HG3.17 were: 1) the extraordinary high 
shape complementarity between the binding pocket of the protein and the substrate 
(while two possible conformers of substrate were able to bind the pocket of HG3, only 
one orientation was detected in HG3.17); 2) the ligand alignament with Asp127, the 
catalytic base, was optimized by evolution resulting in an unusual short hydrogen bond; 
and 3) a new catalytic group, Gln50, stabilized the development of a negative charge in 
the TS.80,81 
Recently, hybrid QM/MM MD simulations for the Kemp elimination in this new 
HG3.17 enzyme have provided a deeper insight into the origin of its catalytic 
efficiency.82 In this case, we have demonstrated the presence of different conformations 
with significant different reactivity. The larger reactivity has been demonstrated to be 
related with a better electrostatic preorganization of the environment that creates a more 
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favourable electrostatic potential for the reaction to proceed. In HG3.17, efforts to 
improve the catalytic properties must be focused in possible mutations increasing the 
preorganization and decreasing the reorganization around the oxyanion hole. Mutations 
should be considered not only in the first shell of residues but in further shells since 
protein electrostatics is a long range property. 
 
3. Diels Alder 
Reactions involving the forming of two carbon-carbon bonds, such as the Diels-Alder 
reaction (see Scheme 2), are very powerful tools in organic synthesis and they have 
been identified in several metabolites. Nevertheless, the number of enzymes catalysing 
this cycloadition reaction, if any, is very low.83,84 In fact, a recent work has claimed for  
the first in vitro characterization of an enzyme committed to the catalysis of a [4+2] 
cycloaddition reaction.85  
 
 
 
Scheme 2. Representation of the Diels Alder cycloaddition reaction 
 
High regioselectivity (orto and para isomers are favoured with respect to the meta), 
diastereoselectivity (endo conformers are favoured with respect to the exo) and 
enantioselectivity (the reaction creates up to four new stereocenters) are probably key 
features that are searched when designing new enzymes catalysing the addition of a 
diene with a dienophile.9,11 The enhanced reaction rate measured in new designed Diels-
Alderases has been proposed to be due to a lowering of the entropy of activation by 
binding the two substrate molecules, also known as “entropy trap”.86 However, a 
reduction in the activation enthalpy has been also proposed as the origin of catalysis.87  
 
3.1 catalytic antibodies 
The first designed catalytic antibody (1E9) showing activity as a Diels-Alderase was 
reported by Hilvert and co-workers.88 Braisted and Schultz, one year later, designed 
another catalytic antibody (39A11) with a different hapten.89 Series of site-directed 
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mutagenesis carried out by Romesberg and Schultz allowed obtaining a mutant that 
displays an increase of one order of magnitude in its catalytic activity.90 Three-
dimensional crystal structures of these antibodies complexed with their respective TSA 
have suggested an almost perfect shape complementarity between protein cavity and the 
substrates in the TS conformation.91,92 A deep analysis of 39A11 structure and its 
mutant revealed the presence of not only a favourable packing but hydrogen bond 
interactions that could be responsible of the control of the relative geometries of the 
bound substrates and the electronic distribution in the dienophile.92 A theoretical study 
on the germline catalytic antibody and its matured form, 39A11, based on hybrid 
QM/MM MD simulations, suggested a complex indirect effect through coupled 
movements of the backbone of the protein and the substrate in the germline, after 
mutation.93 These results stress the importance of backbone flexibility in docking 
studies and in the design of new enzymes. 
A combination of experimental studies and quantum mechanical gas phase calculations, 
carried out by Gouverneur et al., was focused on the stereoselectivity of newly 
generated catalytic antibodies. In particular, the cycloaddition between trans-1-N-
acylamino-1,3-butadiene and N,N-dimethylacrylamide was used to explore the control 
of the endo/exo and absolute configuration of the eight possible reaction products.94 
These substrates were in fact the ones used in the de novo design of new Diels-Alderase, 
as shown in next section. A new catalytic antibody, 13G5, was made to catalyse the 
disfavoured exo Diels-Alder transformation, yielding a single regioisomer in high 
enantiomeric excess.95 This surprising absolute enantioselectivity of 13G5 was 
explained based on gas phase quantum mechanical calculations followed by docking 
and MD simulations.96 
 
3.2. de novo design of new enzymes 
The first de novo design of an enzyme catalysing the bimolecular Diels-Alder 
cycloaddition reaction, with high stereoselectivity and substrate specificity was 
performed by Siegel et al.18 After studying the normal-electron-demand reaction by 
quantum mechanics in gas phase, frontier molecular orbital analysis dictated that 
narrowing the energy gap between the highest occupied molecular orbital (HOMO) of 
the diene with the lowest unoccupied molecular orbital (LUMO) of the dienophile 
should reduce the activation energy and thus it would increase the rate of the reaction. 
This was achieved by positioning a hydrogen bond acceptor to interact with the former 
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(raising the energy of the HOMO) and a hydrogen bond donor to interact with the later 
(thus lowering the energy of the LUMO). These electrostatic requirements were added 
to efforts to improve the binding of the substrates in optimal position in the active site 
of the designed enzyme. The design process starts from generating three dimensional 
models of minimal active sites (theozymes) that, in this case, consist in a glutamine or 
an asparagine to accept hydrogen bond from the N-H moiety of the diene carbamate, 
and a serine, threonine or tyrosine to donate a hydrogen bond to the carbonyl oxygen of 
the dienophile amide moiety. Afterwards, RosettaMatch21 program was used to search 
stable protein scaffolds that allow the theozyme to be placed without making substantial 
steric clashes with the protein backbone. Then, RosettaDesign24,25 was used to optimize 
the set of putative stable proteins. And finally, a reduced number of designs were 
selected for experimental validation proving that only two of them (DA_20 and DA_42) 
had catalytic activity. After rounds of directed evolution, further improvement of 
catalytic activity of DA_20_10 (100-fold over the original design) was obtained, with 
high stereoselectivity that favoured formation of only one of the stereoisomers (3R,4S). 
De novo design can be improved if backbone flexibility is considered. In this sense, the 
search for adequate conformations can be enhanced with creative strategies such as the 
one used by the Foldit multiplayer online game.97 In this game, players compete and 
collaborate solving structure refinements problems where backbone flexibility is 
considered. This strategy was applied to remodel the backbone of DA_20_10 Diels-
Alderase to enable additional interactions with the substrates, resulting in a design 
(CE6) with a modest increase of the enzymatic activity of about 20-fold in kcat.98 
Rounds of directed evolution were used by Hilvert and coworkers to obtain a Diels-
Alderase (CE20) 6-times more efficient than CE6, reshaping the active site pocket for a 
better substrate preorganization and TS stabilization.99 
A different semirational combinatorial design protocol has been used by Brinck and co-
workers to design new Diels-Alderases with significant rate accelerations.100,101,102 The 
computational protocol employs molecular docking, MD and quantum chemical 
calculations at DFT level to find reasonable candidate protein and substrate 
combinations for which protein-substrate interactions were optimized. The estimation of 
the free energy of activation is based on two steps; the free energy difference going 
from the bound state to conformations named as the “near attack-conformation” 
(NAC),103 and the energy required to go from NAC to the TS. The first term is 
computed from the MD simulations while the second term is derived from the DFT 
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calculations. In particular, efforts were focused in finding and optimizing a protein 
structure for a suitable oxyanion hole that would stabilize the LUMO of the 
dienophile,101 or in developing a route based on in situ acid-base catalysed diene 
generation.102 
Other strategies to obtain new Diels-Alderases based on the use of metalloenzymes will 
be presented in section 5. 
 
4. Retro-Aldol reaction 
The Retro-Aldol reaction, in contrast to previous presented reactions, consists in a 
multi-step process that results in a C-C bond breaking. The reaction mechanism 
involves a nucleophilic lysine and the formation of an iminium intermediate (see 
Scheme 3). 
 
 
 
Scheme 3. Representation of the Retro-Aldol reaction mechanism 
 
To account for the multistep reaction mechanisms, the designed new enzyme has to 
present an active site simultaneously compatible with different TSs and intermediates. 
Thus, there must be a compromise between structural reorganization during the catalytic 
process and the preorganization of the active site for such multistep enzyme catalysed 
reaction. The enzyme must present some motions to reach some degree of active site 
reorganization to stabilize each TS. Hilvert, Houk and co-workers have stated that these 
motions may be divided into intrastep and interstep reorganization motions.104 
 
18 
4.1 catalytic antibodies 
The first catalytic antibodies that showed activity for the Aldol reaction, 38C2 and 
33F12,105 were generated to catalyse the carbon-carbon bond formation. These 
antibodies showed to also catalyse the Retro-Aldol reaction.106,107 Later, new aldolase 
catalytic antibodies were designed with special attention to the enantio- and 
diastereoselectivity.108 The mechanism for antibody catalysis of this reaction mimics 
that used by natural class I aldolase enzymes that utilize the ε-amino group of an active 
site lysine residue to form a Shiff base with the substrate (see Scheme 3). X-ray 
crystallographic studies on 33F12 confirmed the presence of a lysine residue, deeply 
buried in a hydrophobic pocket at the base of the binding site, thereby accounting for its 
perturbed pKa.109 Further structural analysis by X-ray diffraction studies gave a direct 
observation of the enamine intermediate.110 Characterization of the Aldol reaction 
mechanism and the proposal of a TSA was made by Arnó and Domingo based on 
quantum mechanical calculations within reduced models.111 
 
4.2. de novo design of new enzymes.  
The first de novo protein design for the Retro-Aldol reaction was published in 2008 by 
Baker and co-workers.19 In this case, four different theozymes were prepared all 
presenting a lysine as a Schiff base. The four active site motifs optimized with quantum 
mechanical methods differ in the general acid/base for deprotonation of the β alcohol: 
Lys/Asp dyad, Tyr, His/Asp dyad or a water molecule. The first proposal was analogous 
to that with D-2-deoxyribose-5-phosphate aldolase, while the other three motifs were 
inspired on the active site of catalytic antibodies, as described above. Using Rosetta 
program24,25 for different active site geometries of the four different motifs that fitted 
into the binding pockets of 71 protein scaffolds, a total of 72 designs were selected for 
experimental characterization. The backbone geometries and side-chain orientation of 
two apo structures solved by X-ray diffraction studies showed an excellent agreement 
with those of the designed enzymes. 32 of them showed detectable retro-aldolase 
activity, although the rate enhancements were between two and three orders of 
magnitude lower than the observed in the catalytic antibodies.107,108 
A computational study of these de novo designed enzymes, based on MD simulations, 
showed that the protein distorted the designed geometry of the substrate-enzyme 
intermediate thus suggesting that the substrate and the catalytic residues were poorly 
packed in the models. These results emphasize that the assumption of the rigid 
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backbone during the computational enzyme designs is one important limitation. Further 
studies on one of the most active new enzymes, corresponding to the last motif, 
revealed that the catalysis was largely due to hydrophobic substrate binding interactions 
and, to a lesser extent, to the shifting of the pKa of the catalytic lysine.112 Structural 
analysis of covalently bound mechanism based inhibitor showed to be similar but not 
identical to the design models.113 Thus, while the substrate appears to be well oriented 
in the binding pocket through hydrophobic interactions with the naphthyl moiety, as 
predicted in the model, the relative orientation with the catalytic lysine is different. The 
bound water network appears to be more extensive, and the bound substrate analog 
exhibits more conformational heterogeneity than typical native enzyme-inhibitor 
complexes.  
In an attempt to improve the efficiency of the new designed enzymes, Hilvert, Baker 
and co-workers optimized the protein via directed evolution,114,115 from the previously 
computationally retro-aldolases that were designed from scratch.19 The specific activity 
was boosted more than 4,400-fold by random mutagenesis and screening, affording 
catalytic efficiencies approaching those of natural enzymes. Surprisingly, dramatic 
changes were detected in the active site by comparison with the original structure. In 
particular, the reactive catalytic lysine and the ordered water molecule were 
unexpectedly abandoned and another lysine residue was found at another binding 
pocket created during the optimization process.115 The drawback of the original 
computational design was the assumption of a rigid protein scaffold during the 
simulations.115 More recently, Hilvert and co-workers have designed a new Retro-
Aldolase by directed evolution from the previously computationally designed RA110.116 
The original activity, that accelerated substrate cleavage by a factor of 12000 over 
background, was increased more than 1000-folds. The X-ray structure of the new 
catalyst with an inhibitor showed, again, substantial deviations from the designed 
model. Finally, Baker and co-workers have investigated an alternative active site design 
in which the catalytic water molecule was replaced by the side chain of a glutamic acid. 
After site-directed evolution, the rate enhanced of the new enzyme, RA110.4-6, was still 
below the best values obtained for catalytic antibodies and the previous example. 
 
5. Artificial Metalloenzymes 
Metalloproteins, which represents almost half of the enzymes in nature, catalyse some 
of the most difficult biological transformations by complex reaction mechanisms.117,118 
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This is the origin of the extensive work devoted to the development of strategies for the 
design of artificial metalloenzymes as stressed in recent reviews.119,120,121,122,123,124,125,126 
One of the main targets in this field is to merge the attractive properties of 
homogeneous catalysis and biocatalysis (see Figure 2). It is envisioned that artificial 
metalloenzymes can combine the best of both worlds; the broad catalytic scope, a 
hallmark of homogeneous catalysis, and the high activity and selectivity under mild 
conditions that characterize enzymatic catalysis. The main structural characteristic of 
metalloenzymes is the presence of a metal-ligand complex that is anchored to the 
biomolecule host and provides the first coordination sphere whereas the host provides 
the second one. Two different anchoring strategies can be used; noncovalent, which 
includes anchoring through supramolecular and dative interactions, and covalent 
anchoring, usually through a cysteine residue.117,118,119,120 Nevertheless, non-native 
functionalities has also been expanded through the incorporation into the protein 
scaffold of metal-containing cofactors not found in nature.118 In nature, proteins 
incorporate metal cofactors such as haem by means of non-covalent and covalent 
interactions.118 The de novo design of an artificial metalloenzyme is also related with 
the modelling of the protein scaffold from first principles. This can imply the redesign 
of a critical loop to improve the key side-chain interactions established with the 
substrate.127 Other efforts have been focused in the engineering of metal-binding sites 
containing cysteine residues in an existing three-helix boundle,128 or the generation of 
combinatorial libraries of de novo proteins (named “artificial superfamilies”) 
containing, for instance, four-helix bundles and presenting catalytic activity for a variety 
of functions.129 It is then not surprising that the border between the de novo protein 
design and the redesign based on existing proteins is not well defined.126,130  
As exposed above, due to the large number of designed metalloenzymes, only selected 
examples will be highlighted in this review. In particular, we will first focus on 
metalloenzymes with catalytic activity in the Diels-Alder reaction. A section devoted to 
the design of proteins with zinc hydrolytic centers will be followed by examples of 
heme no-heme artificial enzymes, and we will finish with some examples of 
technologies based on the supramolecular anchoring approach. 
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Figure 2. Schematic representation of an artificial metalloenzyme, where a metal ligand 
complex is posed in the cavity of an enzyme by means of different possible anchoring 
strategies.  
 
5.1 Diels-Alder 
A metalloenzyme that catalyses the Diels-Alder cycloadition of azachalcone (see 
Scheme 4) have been created by designing a Cu(II)-specific binding site with 
coordinating amino acids at geometrically appropriate positions in a thermoestable host 
protein (tHisF).131,132 The catalytic activity has been assumed to be due to the five-
membered chelate structure made by the lone electron pairs at the carbonyl O atom and 
the pyridine N atom, activating the substrate by lowering the energy of the LUMO. 
Authors observed notable enantioselectivity, enhanced endo-selectivity, and higher 
reaction rate. The same asymmetric Diels-Alder reaction has been used to design an 
artificial metalloenzyme from a different protein scaffold, a sterol carrier protein type 2 
like domain (SCP-2L), obtaining a promising enantioselectivity of 25% ee and good 
endo selectivity133  
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Scheme 4. Representation of the Diels-Alder cycloadition between azachalcone and 
cyclopentadiene 
 
 
 
Figure 3. Schematic representation of of proposed artificial metalloenzymes based on 
Cu(II) complexes grafted on the dimer interface of a protein. 
 
Roelfes group, using a different strategy, has also studied the Diels-Alder cycloadition 
between azachalcone and cyclopentadiene as a benchmark reaction to design new 
metaloenzymes.134 First, an active site is generated on the dimer interface of the 
Lactococcal multidrug resistance Regulator (LmrR) (see Figure 3). A copper(II) 
phenantroline complex was covalent anchored in the hydrophobic pocket of the protein 
using a cysteine conjugation strategy. The resulting artificial metaloenzyme showed 
excellent enantioselectivity (up to 97%) and diastereoselectivity (endo/exo 95:5).134  
Similar to proteins, DNA can offer a defined chiral second coordination sphere for the 
construction of an artificial metalloenzyme, as introduced by Roelfes and Feringa for 
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the asymmetric Diels-Alder catalysis.135,136,137 A DNA-based catalyst was designed 
using a copper complex of a non-chiral ligand that can bind to DNA (see Figure 4). The 
active Cu2+ center was brought into proximity of the DNA double helix, allowing 
transfer of chirality from DNA to the product of Cu2+-catalyzed Diels-Alder reaction. 
Products were obtained with very high diastereoselectivities and enantioselectivities 
(83-98%).135,136 As explained, the catalytic ensemble comprises an intercalator and a 
copper-chelating moiety. In the first generation, these two moieties were linked by a 
spacer, whereas in the second generation both sites are integrated into a single 
bipyridine moiety and thus the reactive copper center is brought into closer contact with 
the chiral environment. These findings underline the fact that the design of the ligand is 
an important factor in the development of this kind of artificial catalysts.117 The second 
generation of catalysts are also capable of enhancing the rate of the reaction up to two 
orders of magnitude.137  
 
 
Figure 4. Schematic representation of of proposed artificial metalloenzymes based on 
modular assembly of a copper complex of a non-chiral ligand to a DNA scaffold. 
 
 
5.2 Zinc Hydrolytic centers 
In the preceding section we have presented two different strategies for the design of 
Diels-Alder metalloenzymes, based on the complexation of a Cu(II) metal ion, or a 
metal complex. In this section we focus in the case metalloenzyme designs based in the 
complexation of just metal ions such as Zn(II) or Fe (II).  
As stated in a recent review by Alexandrova and co-workers,138 the selection of the 
catalytic metal in the process of metalloenzymes evolution can be due to factors other 
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than optimizing catalysis alone, such as metal availability or toxicity. Enzymes evolved 
under these restrictions are good enough for vital purposes but they do not necessarily 
reach the best catalytic performance. Consequently, these limitation provides an 
excellent opportunity to improve the catalytic properties of these enzymes in the 
laboratory substituting the metal for another one. In this sense, computational 
predictions based on DFT calculations have shown that β-lactamases could be improved 
via replacement of zinc by nickel.139 It must be taken into account that one of the main 
limitations in the computational study of metalloenzymes is the description of metal 
ions and its coordination shell. Typically, classical force fields and semiempirical 
methods, and also some DFT functional or ab initio treatments, can lead to erroneous 
descriptions of the coordination index of the metal and in particular its change during 
the reaction process. 
Active site redesign changing metal ions, has been found to be a promising strategy to 
improve not only the primary catalytic reaction but also secondary processes in 
promiscuous enzymes. As an example, Leitgeb and Nidetzky enhanced the secondary 
hydrolase activity of a promiscuous oxygenase β-Diketone-cleaving enzyme by 
changing Fe2+ to Zn2+ in the active site.140 
Another strategy to design metalloproteins was reported by the Baker group as an 
extension of their de novo enzyme design methodology to exploit the reactivity of metal 
ions in existing enzyme active sites.141 In particular, the method was based in the 
redesign of existing suitable native crystallized proteins containing mononuclear zinc 
centers with at least one free coordination site. TS models of organophosphate 
hydrolase reaction were modelled into the zinc sites and additional hydrogen-bond 
interactions were identified using their RosettaMatch program. After maturation using 
directed evolution, a 107-fold increase in the catalytic activity was obtained. Warshel 
and co-workers have suggested that designs on mononuclear zinc metalloenzyme can be 
improved by optimizing the preorganization of the environment, which is the key factor 
in enzyme catalysis.142  
Recently, Pecoraro and co-workers have designed efficient hydrolytic zinc sites to 
create an artificial hydrolase, with catalytic activity that compares well with natural 
carbonic anhydrases.143,144,145 X-ray crystallography showed that the designed protein 
contained two different metal ions; Zn(II), which is important for catalysis, and a Hg(II) 
ion, which provides structural stability. In these hydrolytic zinc metalloenzymes, it was 
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demonstrated the influence of location of the active site formed by the metal and three 
histidine residues in a three-stranded coiled-coil oligopeptide.  
Kuhlman and co-workers serendipitously discovered that a computationally designed 
Zn(II) site at the interface of a homodimer (MID1-Zn) could effectively catalyse 
carboxyester and phosphoester hydrolysis.146,147 A Rosetta-based approach was used for 
the rational design of a protein monomer to form a zinc-mediated, symmetric 
homodimer. The computationally designed zinc-mediated protein showed a good 
overall agreement with the X-ray structure,146 and suggested that the clefts formed by 
the protein-protein interactions were well suited for creating enzyme active sites.147  
 
5.3 heme no-heme artificial enzymes 
This section deals with catalysis by bimetallic centers, where one of the metals forms 
part of a heme complex and the other is directly complexed by enzymatic residues. 
Example of key reactions that are catalysed by heme no-heme artificial enzymes are the 
reduction of NO to NO2 and the reduction of O2 to H2O. Nitric oxide reductase (NOR), 
is a metalloenzyme that participate in the nitrification pathway and is critical for life. A 
first example of the success of designing a NOR artificial enzyme is the conversion 
from a myoglobin by introducing a non-heme FeB site in the distal heme pocket. One 
glutamate residue and two histidines were required in this FeB active site for both iron 
binding and NOR activity.148,149 The introduction of a second glutamate residue in a 
myoglobin protein scaffold, that appears to interact with a water molecule forming a 
hydrogen bonding network, was demonstrated to increase 100-fold the NOR activity. It 
was suggested the importance of this hydrogen bonding network in facilitating the 
proton delivery for NOR reactivity.150 Replacing the Fe metal in the no-heme center by 
other cations shows that Cu dependent NOR activity was significantly higher than that 
of Fe in the same metal binding site.151 Molecular dynamics simulations on a mutant 
with an additional distal histidine (L29H) and a distal tyrosine (F43Y) in the heme 
pocket, to mimic the active site of cytochrome cd1 nitrite reductase from Ps. 
aeruginosa, revealed that the new protein contains the necessary structural features of 
the later. This strategy provides rationality for protein design and can guide further 
protein engineering.152  
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Figure 5. Crystal structure of the binuclear center of cytochrome ba3 oxidase (PDB code 
1XME).  
 
In a similar way, myoglobins have been also engineering into a heme copper oxidase 
(HCO) that performs the reduction of oxygen to water, by introducing a histidine 
residue near the heme site to create a CuB site. Thus, the corresponding active site 
consists of a heterobinuclear center containing a heme Fe and a histidine ligated Cu 
(CuB) as well as a post-translationally installed crosslink between a tyrosine residue and 
a close lying histidine (see Figure 5). The designed functional metalloenzyme showed a 
HCO activity with over one thousand turnovers.153,154 Genetic incorporation of an 
unnatural aminoacid, which mimics the cross-linked Tyr-His ligand, allowed stressing 
the effect of Tyr and His with and without cross-linking (obtained after a selected 
mutation that avoided its formation). The new designed model achieved higher activity 
for O2-reduction, with an eightfold increase in selectivity and a threefold increase in 
catalytic turnover.154 
 
5.4 Supramolecular Anchoring Approach 
The concept of introducing a homogeneous catalyst within a protein environment to 
create artificial metalloenzymes was first proposed by Wilson and Whitesides in the 
early 1970s.155 Examples of biomolecular scaffolds capable of embedding a 
catalytically active transition metal complex include avidin, streptavidin, bovine serum 
albumin and myoglobin.134 The extraordinary affinity of the molecule biotin for either 
avidin or streptavidin makes this case as one of the most employed systems. Moreover, 
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these protein scaffolds present a binding pocket that is large enough to bind the 
organometallic catalyst and still leave space for the substrate.117,134 Biotin is covalently 
linked to a catalyst precursor, a metal complex, ensuring that the metal moiety is 
quantitatively incorporated within the host protein upon stoichiometric addition of 
(strep)avidin (see Figure 6).156 Another important advantage of these hybrid 
supramolecular catalysts is that, since the biotynilated catalyst precursor and the host 
protein are developed separately of one another, they can be optimized separately 
through synthetic and molecular biology approaches.126  
 
 
 
Figure 6. Schematic representation of artificial metalloenzymes based on the biotin-
avidin technology. 
 
Computational simulations of protein-ligand docking and experimental studies based on 
electron paramagnetic resonance spectroscopy, chemical modifications and mutagenesis 
studies, suggest that a vanadyl ion is located within the biotin-binding pocket and 
interacts only via the second coordination sphere contacts with strep(avidin).157 Many 
reactions have been catalysed following this synthetic strategy.156,158 Interestingly, a 
theoretical study based on MD simulations has shown significant flexibility of the 
biotinylated ligand in artificial metalloenzymes based on streptavidin.159 The creation of 
a bifunctional artificial metalloenzyme with a reduced flexibility was generated by 
introducing a base (an aspartate or a glutamate residue) into the streptavidin in concert 
with a docked biotinylated rhodium(III) complex to enable asymmetric carbon-
hydrogen activation.160 A similar strategy has been used to improve the catalytic 
performance in the transfer hydrogenation of imines by an in silico design of an 
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artificial metalloenzyme. The designed structure, confirmed by X-ray crystallography, 
contained a suitable positioned histidine residue that firmly anchor, via a dative bond, a 
biotinylated rhodium piano stool complex within streptavidin.161  
An integrated computational approach, combining protein-ligand docking, quantum 
mechanical, and QM/MM calculations, has been used to provide a deep insight into the 
mechanistic behaviour of the first artificial metalloenzyme generated by supramolecular 
anchoring approach able to reduce enantioselectivily cyclic imines.162 The identification 
of the TS geometries leading to (R)- and (S)-reduction products in the presence of the 
full hybrid system allowed the authors to identify the distinctive pattern of interactions 
between the substrate and the binding site, responsible of the observed results. 
 
6 Future perspectives 
The design of new biocatalysts is an ambitious target that requires a detailed knowledge 
of the reaction to be catalyzed, and how natural enzymes achieve their catalytic 
efficiency in mild environmental conditions. In this regard, the combination of 
experimental and computational techniques has been revealed as a very reasonable 
strategy. As mentioned by Hilvert and co-workers, precision is essential for 
development of new biocatalysts based on the combination of de novo computational 
design with laboratory evolution techniques.80 New and more sophisticated engineering 
protocols are required to approach to the rate constants usually observed in native 
enzyme catalysed processes. 
The success in the design of new enzymes with new functions has potential applications 
in different chemical and biochemical industries. This review has been focused on the 
advances obtained in the field of the de novo design during the last years using 
examples of increasing complexity. Kemp, Diels-Alder and retro-aldol, three of the 
most popular benchmarks reactions in the field designing new enzymes have been used 
to illustrate recent achievements. The first one has been chosen due to its simplicity and 
the fact that no natural enzyme catalyses this reaction. Diels-Alder is a bimolecular 
reaction that can produce many different isomers. The control of the products specificity 
is a feature that, in fact, can be more important than enhancing its rate constant. Finally, 
the design of new biocatalysts for the retro-aldol reaction represents an additional 
difficulty since the reaction takes place in several chemical steps. Thus, the new enzyme 
must properly represent the features of several TSs and, at least, one intermediate. 
Conformational changes of the protein to form the Michaelis complex (preorganization) 
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has to take place along the reaction to stabilize different intermediates of the different 
steps. This requires a coupling between the reaction progress and the conformational 
changes of the protein to get a proper preorganization for each chemical step. Finally, a 
section has been devoted to the particularities of the design of metal-containing 
enzymes, a promising field due to the combination of the best features of homogeneous 
catalysis and enzyme catalysis; the broad catalytic scope and the high activity and 
selectivity under mild conditions, respectively. Nevertheless, since one or more metal 
ions, or metal complexes, are involved in the process, the difficulties of designing this 
kind of biocatalysts dramatically increase. 
From the pioneer work of Mayo and co-workers in the de novo design of an esterase,14 
several groups have focused the attention into the design of catalysts for the three 
mentioned reactions by means of similar strategies, still with a limited success. 
Different improvements have been incorporated during the past decade, such as partially 
considering the flexibility of the backbone of the template protein or the use of non-
canonical amino acids. Nevertheless, the rate enhancement reached by these new 
biocatalysts is usually far from those of natural enzymes. As mentioned by Baker,37 and 
stressed in the introduction section of this review, the de novo based design strategies 
can fail due to an imperfect theozyme, which does not represent the real TS of the 
reaction, a distortion of the designed active site into a given protein scaffold, or due to 
the effect of the long range electrostatic interactions and/or protein dynamics that can be 
incompatible with catalysis. Nevertheless, long range electrostatic interactions, their 
knowledge and simulation, can be used as a guide to the design of the new enzyme, 
instead of considering them as a limitation. Mutations far from the active site can be 
proposed to improve this kind of interactions, and the flexibility of the protein must be 
considered in any step of the design protocol. It must be kept in mind that while efforts 
have been focused exclusively in the chemical step of the reaction to be catalyzed, it 
will be interesting to extend these methodologies to analyze the influence of mutations 
on steps like substrate binding or product release. This could improve the substrate 
affinity and/or the catalytic turnover, respectively. Increasing the preorganization of the 
active site would likely improve the catalytic efficiency. In addition, a more complete 
design strategy should consider not only the TS stabilization but the differential 
stabilization of the TS with respect to the reactants. Thus, further improvements on the 
de novo design of new enzymes will be probably based in better localization and 
characterization of the TS and reactants by means of high level computational methods. 
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The use of flexible molecular models treated by QM/MM multiscale methods can be the 
bedrock of future successful studies. A proper sampling of the protein conformational 
landscape, performed by Molecular Dynamics simulations, could give also information 
related with the capability of a designed enzyme to catalyze a multistep-process. In 
these more complex targets, the active site of the enzyme has to be prepared not only to 
stabilize the TS but to accommodate and stabilize the system for different steps. In this 
refinement, the improved packing should be considered as not only a mechanical 
embedding but also an electrostatic one. The role of not only residues belonging to the 
first shell of the active site should be taken into account. 
In the next future we should be able to design a particular amino acid sequence that will 
fold into a particular structure with the desired function from scratch. This is the final 
goal in rational design of proteins.  
 
Acknowledgements 
This work was supported by the Spanish Ministerio de Economía y Competitividad for 
project CTQ2012-36253-C03, Universitat Jaume I (project P1·1B2014-26), Generalitat 
Valenciana (PROMETEOII/2014/022 and ACOMP/2014/277 projects), Polish National 
Center for Science (NCN) (grant 2011/02/A/ ST4/00246, 2012−2017), the Polish 
Ministry of Science and Higher Education ("Iuventus Plus" program project no. 
0478/IP3/2015/73, 2015-2016) and the USA National Institute of Health (ref. NIH R01 
GM065368). Authors acknowledge computational resources from the Servei 
d’Informàtica of Universitat de València on the ‘Tirant’ supercomputer and the Servei 
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